Research Summary

Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Theranostics. He serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford.

Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.

An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He current serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.

Expertise:
Abdominal Imaging and Nuclear Medicine, and Molecular Imaging and Therapeutics

Professional Interests:
Novel imaging agents, PET/MR, prostate cancer, neuroendocrine tumor, radioligand therapy

Education and Training:
• Medical School: Stanford University School of Medicine, California
• Internship: Kaiser Permanente, San Francisco, California
• Residency: University of California, San Francisco - Diagnostic Radiology
• Fellowship: Stanford Medical Center, California - Body MRI and Nuclear Medicine
• California Medical License
• American Board of Radiology, Certificate in Diagnostic Radiology
• American Board of Nuclear Medicine, Certificate in Nuclear Medicine

Research Funding

  • July 1, 2019 - June 30, 2026 - MELT: Modulation of PSMA Expression for Lutetium Therapy , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2023 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • Distinguished Scientist, Western Region Society of Nuclear Medicine, 2025
  • Wahl Mid-Career Leadership Award, Education and Research Foundation for Nuclear Medicine and Molecular Imaging, 2024
  • Hal O’Brien Rising Star Award Winner, Society of Nuclear Medicine and Molecular Imaging, 2020
  • Theragnostics Investigator Award, North American Neuroendocrine Tumor Society, 2018
  • Young Investigator Award, Prostate Cancer Foundation, 2017
  • Henkin Fellowship, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Marc Tetalman Award, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Wylie J. Dodds Research Award, Society of Abdominal Radiology, 2014
  • Roentgen Resident/Fellow Research Award, Radiological Society of North America, 2012
  • Alexander Margulis Society Outstanding Research Award, University of California, San Francisco, 2012
  • Presidents Circle Research Resident Grant, Radiological Society of North America, 2010
  • W.S. Moore Award Nominee, ISMRM, 2007
  • Trainee Research Prize, Radiological Society of North America, 2006

Selected Publications

  1. Taplin ME, Parikh RA, Rumble RB, Naqvi SAA, Nahhat F, Dias MF, Hope TA, He H, Hotte SJ, Emamekhoo H, Murad MH, Celano P, Kungel TM, Hentzen S, Marzalik JS, Serzan MT, Riaz IB. Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4. J Clin Oncol. 2026 Aug 06; 101200JCO2601898. View on PubMed
  2. Hong CW, Hassan O, Tang F, Moradpour M, Jiang F, Gill RM, Choi HH, Houshmand S, Wang K, Hope TA, Behr SC. Diagnostic performance of CT/MRI LI-RADS radiation treatment response algorithm v2024 for Y-90 radioembolization. Eur J Radiol. 2026 Jul 14; 204:113079. View on PubMed
  3. Duh PJ, Sederias I, Zimmerer VC, Akkad H, Leff AP, Hope T, Crinion J. Uncovering hidden pathways: structural brain networks under connected speech in post-stroke aphasia. Brain Commun. 2026; 8(4):fcag260. View on PubMed
  4. Deroose CM, Leupe H, Hicks RJ, Virgolini I, Braat AJAT, Mittra ES, Albert NL, Bailey DL, Bodei L, Chan DL, Dekervel J, Denecke T, Dromain C, Falconi M, Fournier L, Grozinsky-Glasberg S, Hofland J, Hope TA, Karfis I, Kos-Kudla B, Koumarianou A, Lamarca A, Litière S, Pavel M, Stroobants S, Strosberg J, Sundin A, Taïeb D, Trikalinos N, Unterrainer M, Verslype C, Vijayvergia N, Wild D, Kjaer A, Ambrosini V, Prasad V. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS). Lancet Oncol. 2026 Aug; 27(8):e392-e402. View on PubMed
  5. Unterrainer LM, Ndlovu H, Hope TA, Unterrainer M, Czernin J, Sathekge M, Calais J. Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer. J Nucl Med. 2026 Jul 01; 67(7):1090-1092. View on PubMed
  6. Uribe C, Iravani A, Savir-Baruch B, Jacene H, Graves SA, Dewaraja YK, Lawhn Heath C, Hope TA. Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT. J Nucl Med. 2026 Jul 01; 67(7):1173-1174. View on PubMed
  7. Moradpour M, Hong CM, Khan S, Tochayi AM, Yadav S, Flavell RR, Emmett L, Hope TA. Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT. Eur Urol Oncol. 2026 Jun 30. View on PubMed
  8. Riaz IB, Rumble RB, Hope TA, Procopio G, Vapiwala N. Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2026 Jun 22; JCO2601001. View on PubMed
  9. McConathy J, Koshkin VS, Menda Y, Rodon J, Goenka AH, Moy RH, Morse S, Demange A, Blumenstein L, Babaoglan B, Aimone P, Hope TA. Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial. Clin Cancer Res. 2026 Jun 01. View on PubMed
  10. Kimura K, Murthy V, Voter AF, Solnes LB, Moradi Tuchayi A, Yadav S, Theus L, Nguyen A, Ludwig V, Holzgreve A, Unterrainer LM, Grogan TR, Czernin J, Hope TA, Gafita A, Calais J. PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program. J Nucl Med. 2026 05 01; 67(5):731-738. View on PubMed
  11. Moradpour M, Moradi Tuchayi A, Yadav S, Jiang F, Burger IA, Pop SG, Surasi DS, Hussein A, Arora I, Aparicio A, de Kouchkovsky I, Flavell RR, Hope TA. Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer. J Nucl Med. 2026 May 01; 67(5):739-743. View on PubMed
  12. Emmett L, Swiha M, Papa N, Subramaniam S, Crumbaker M, Joshua AM, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Pathmanandavel S, Hope T, Ayati N, Hofman MS, Sandhu S, Niu C, Martin AJ, Thomas H, Stockler MR, Davis ID, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nat Cancer. 2026 Apr; 7(4):622-630. View on PubMed
  13. Moradpour M, Moradi Tochayi A, Houshmand S, Nwihim S, Jiang F, Yadav S, Lindsay S, Bergsland EK, Hope TA. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2026 Apr 09. View on PubMed
  14. Kiess AP, Sunderland JJ, Scott PJH, Hope TA. Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies. J Nucl Med. 2026 Apr 09. View on PubMed
  15. Karpinski MJ, Civan C, Rauscher I, Güven O, Eiber M, Hoberück S, Miederer M, Bundschuh RA, Hölscher T, Calais J, Theus L, Nguyen AT, Scholtissek H, Lapa C, Di Giorgio A, Farolfi A, Ufton D, Drzezga A, Kunikowska J, Pelka K, Evangelista L, Bauman G, Alçin G, Beintner-Skawran S, Rohani MFM, Miksch J, Hüsing A, Kesch C, Herrmann K, Stuschke M, Umutlu L, Gafita A, Hofman MS, Hope TA, Goffin K, Kind F, Pizzuto DA, Soeterik TFW, Kömek H, Emmett L, Vondrak A, Pinter T, Lanfranchi F, Bauckneht M, Unterrainer LM, Holzgreve A, Bjartell A, Trägårdh E, Rasul S, Miszczyk M, Bögemann M, Rodriguez SantAnna Jauregui N, Schäfers M, Rahbar K, Hadaschik BA, Fendler WP, PROMISE Registry Group. New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Lancet Oncol. 2026 Apr; 27(4):480-490. View on PubMed
  16. Morris MJ, Hope TA, Sartor O. Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop. J Nucl Med. 2026 03 02; 67(3):345-347. View on PubMed
  17. Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH, Chen DL, Chi KN, Childs DS, Dahut W, Emmett L, Fizazi K, Gafita A, George DJ, Hermann K, Hofman MS, Hope T, Hussain M, Kelly WK, Kessler E, Kuo PH, Lang J, Liu G, Marshall CH, Morgans AK, McKay RR, Nanus D, Nelson P, Paller C, Reichert ZR, Ryan CJ, Sartor AO, Schöder H, Schwartz LH, Sharifi N, Stadler WM, Stein M, Sternberg CN, Szmulewitz RZ, Tagawa ST, Sokolova AO, Wyatt AW, Yamoah K, Yu EY, Halabi S, Scher HI, PCWG4 Writing Group. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. J Clin Oncol. 2026 May; 44(13):1249-1265. View on PubMed
  18. Taplin ME, Riaz IB, Rumble RB, Naqvi SAA, Hope TA, Dias MF, He H, Hotte SJ, Emamekhoo H, Murad MH, Celano P, Kungel TM, Hentzen S, Serzan MT, Parikh RA. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1. J Clin Oncol. 2026 Feb 20; 44(6):e1-e14. View on PubMed
  19. Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K. Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP). Future Oncol. 2025 Nov; 21(27):3491-3498. View on PubMed
  20. Chen WS, Tuchayi AM, Sabbagh A, Kim I, Porter E, Ashraf-Ganjouei A, Li YR, Witztum A, Rajagopal A, Seyedin SN, Juarez R, Carroll PR, Feng FY, Small EJ, Hope TA, Hong JC. Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JNCI Cancer Spectr. 2025 Nov 03; 9(6). View on PubMed

Go to UCSF Profiles, powered by CTSI